## Ray Moynihan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2052038/publications.pdf

Version: 2024-02-01

54 4,008 24 51 papers citations h-index g-index

55 55 55 3804

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Interactions with the pharmaceutical industry and the practice, knowledge and beliefs of medical oncologists and clinical haematologists: a systematic review. British Journal of Cancer, 2022, 126, 144-161.	2.9	5
2	Australian Cancer Physicians and the Pharmaceutical Industry: A Survey of Attitudes and Interactions. JCO Oncology Practice, 2022, 18, e1154-e1163.	1.4	3
3	A novel methodological framework was described for detecting and quantifying overdiagnosis. Journal of Clinical Epidemiology, 2022, 148, 146-159.	2.4	3
4	Interventions to improve media coverage of medical research: a codesigned feasibility and acceptability study with Australian journalists. BMJ Open, 2022, 12, e062706.	0.8	3
5	Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review. BMJ Open, 2021, 11, e045343.	0.8	671
6	Journalists' views on media coverage of medical tests and overdiagnosis: a qualitative study. BMJ Open, 2021, 11, e043991.	0.8	12
7	Head of bed elevation to relieve gastroesophageal reflux symptoms: a systematic review. BMC Family Practice, 2021, 22, 24.	2.9	10
8	Covid-19: an opportunity to reduce unnecessary healthcare. BMJ, The, 2020, 370, m2752.	3.0	71
9	Media coverage of calls to rename low-risk cancers: a content analysis. BMJ Open, 2020, 10, e038087.	0.8	2
10	Mixed methods evaluation of workshops for citizen health advocates about financial conflicts of interests in healthcare. BMJ Open, 2020, 10, e034195.	0.8	5
11	The introduction and demise of full-body computed tomography (CT) scanning in Australia: implications for preventing overdiagnosis. Critical Public Health, 2020, , 1-13.	1.4	O
12	Financial ties between leaders of influential US professional medical associations and industry: cross sectional study. BMJ, The, 2020, 369, m1505.	3.0	49
13	Commercial influence and covid-19. BMJ, The, 2020, 369, m2456.	3.0	17
14	Commercial interests, transparency, and independence: a call for submissions. BMJ: British Medical Journal, 2019, 365, 11706.	2.4	15
15	Reforming disease definitions: a new primary care led, people-centred approach. BMJ Evidence-Based Medicine, 2019, 24, 170-173.	1.7	36
16	Public perceptions of changing the terminology for low-risk thyroid cancer: a qualitative focus group study. BMJ Open, 2019, 9, e025820.	0.8	14
17	Media Coverage of the Benefits and Harms of Testing the Healthy: a protocol for a descriptive study. BMJ Open, 2019, 9, e029532.	0.8	6
18	Resisting recommended treatment for prostate cancer: a qualitative analysis of the lived experience of possible overdiagnosis. BMJ Open, 2019, 9, e026960.	0.8	12

#	Article	IF	Citations
19	Cochrane Sustainable Healthcare: evidence for action on too much medicine. The Cochrane Library, 2019, 12, ED000143.	1.5	9
20	Pathways to independence: towards producing and using trustworthy evidence. BMJ, The, 2019, 367, l6576.	3.0	79
21	Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and overÂactive bladder syndrome? An Australian cohort study. BMJ Open, 2018, 8, e019027.	0.8	19
22	Patients' experiences of diagnosis and management of papillary thyroid microcarcinoma: a qualitative study. BMC Cancer, 2018, 18, 242.	1.1	54
23	Australia is responding to the complex challenge of overdiagnosis. Medical Journal of Australia, 2018, 209, 332-334.	0.8	17
24	Effect of a Change in Papillary Thyroid Cancer Terminology on Anxiety Levels and Treatment Preferences. JAMA Otolaryngology - Head and Neck Surgery, 2018, 144, 867.	1.2	39
25	Renaming low risk conditions labelled as cancer. BMJ: British Medical Journal, 2018, 362, k3322.	2.4	31
26	Toward a Healthier Patient Voice. JAMA Internal Medicine, 2017, 177, 350.	2.6	20
27	Clinicians' Views on Management and Terminology for Papillary Thyroid Microcarcinoma: A Qualitative Study. Thyroid, 2017, 27, 661-671.	2.4	62
28	Improving coverage of medical research in a changing media environment. Cmaj, 2017, 189, E551-E552.	0.9	1
29	Mapping the drivers of overdiagnosis to potential solutions. BMJ: British Medical Journal, 2017, 358, j3879.	2.4	108
30	A cross-sectional analysis of pharmaceutical industry-funded events for health professionals in Australia. BMJ Open, 2017, 7, e016701.	0.8	25
31	Words do matter: a systematic review on how different terminology for the same condition influences management preferences. BMJ Open, 2017, 7, e014129.	0.8	91
32	Communicating about overdiagnosis: Learning from community focus groups on osteoporosis. PLoS ONE, 2017, 12, e0170142.	1.1	16
33	Public Opinions about Overdiagnosis: A National Community Survey. PLoS ONE, 2015, 10, e0125165.	1.1	48
34	How different terminology for ductal carcinoma in situ impacts women's concern and treatment preferences: a randomised comparison within a national community survey. BMJ Open, 2015, 5, e008094.	0.8	46
35	What do you think overdiagnosis means? A qualitative analysis of responses from a national community survey of Australians. BMJ Open, 2015, 5, e007436-e007436.	0.8	31
36	How different terminology for ductal carcinoma in situ (DCIS) impacts women's concern and management preferences: A qualitative study. Breast, 2015, 24, 673-679.	0.9	21

#	Article	IF	Citations
37	Using Evidence to Combat Overdiagnosis and Overtreatment: Evaluating Treatments, Tests, and Disease Definitions in the Time of Too Much. PLoS Medicine, 2014, 11, e1001655.	3.9	75
38	Too Much Medicine: from evidence to action. BMJ, The, 2013, 347, f7141-f7141.	3.0	21
39	The future of medicine lies in truly shared decision making. BMJ, The, 2013, 346, f2789-f2789.	3.0	9
40	What is disease? And why it's a healthy question. BMJ, The, 2013, 346, f107-f107.	3.0	4
41	Expanding Disease Definitions in Guidelines and Expert Panel Ties to Industry: A Cross-sectional Study of Common Conditions in the United States. PLoS Medicine, 2013, 10, e1001500.	3.9	123
42	Australia moves closer to full disclosure of drug company payments to doctors. BMJ, The, 2013, 346, f3960-f3960.	3.0	0
43	Science of overdiagnosis to be served up with a good dose of humility. BMJ, The, 2013, 347, f5157-f5157.	3.0	5
44	Chronic kidney disease controversy: how expanding definitions are unnecessarily labelling many people as diseased. BMJ, The, 2013, 347, f4298-f4298.	3.0	127
45	Too much medicine; too little care. BMJ, The, 2013, 347, f4247-f4247.	3.0	114
46	Preventing overdiagnosis: how to stop harming the healthy. BMJ, The, 2012, 344, e3502-e3502.	3.0	512
47	Too much medicine, not enough mirth. BMJ, The, 2012, 345, e7116-e7116.	3.0	5
48	Job insecurity contributes to poor health. BMJ, The, 2012, 345, e5183-e5183.	3.0	4
49	Reasons to be hopeful: streams of renewal in healthcare. BMJ, The, 2012, 345, e6042-e6042.	3.0	1
50	Has novelty in healthcare gone a little stale?. BMJ, The, 2012, 344, e4229-e4229.	3.0	0
51	Disease Mongering Is Now Part of the Global Health Debate. PLoS Medicine, 2008, 5, e106.	3.9	46
52	The Fight against Disease Mongering: Generating Knowledge for Action. PLoS Medicine, 2006, 3, e191.	3.9	175
53	Selling sickness: the pharmaceutical industry and disease mongering * Commentary: Medicalisation of risk factors. BMJ: British Medical Journal, 2002, 324, 886-891.	2.4	676
54	Coverage by the News Media of the Benefits and Risks of Medications. New England Journal of Medicine, 2000, 342, 1645-1650.	13.9	448